Inovio Pharmaceuticals (NASDAQ:INO – Free Report) had its price objective cut by Royal Bank of Canada from $7.00 to $6.00 in a report released on Friday morning,Benzinga reports.They currently ...
Analyst Stephens covers INOVIO Pharmaceuticals highlighting its diverse clinical pipeline and FDA's consideration of INO-3107 Phase 1/2 trials for Accelerated Approval. Potential as the first non ...
Investopedia / Alice Morgan The Federal Reserve cut its benchmark interest rate Thursday by 0.25 percentage points to a range of 4.5% to 4.75%, its lowest since February 2023. The Fed is cutting ...